Boston Scientific has announced key data, including one late-breaking clinical trial, that will be featured at the 37th Annual Scientific Sessions of the Heart Rhythm Society (HRS) in San Francisco on May 4-7 2016.
Data from the EFFORTLESS study, the first large-scale, multinational, post-market analysis of safety and efficacy of the subcutaneous implantable defibrillator (S-ICD), will be featured at the late-breaking clinical trial session on Friday, May 6. Other presentations and abstracts of interest include:
- New, pre-clinical data showcasing the company’s modular therapy approach and communications compatibility between its leadless pacemaker and the Emblem S-ICD system
- Insights and results of the mapping data obtained using the high-density, high-resolution Rhythmia mapping system
- Performance and usage information about the Acuity X4 quadripolar left ventricular (LV) leads, which were approved by the US Food and Drug Administration (FDA) earlier this year
- Cost-effectiveness and safety data related to the Watchman left atrial appendage closure (LAAC) device
Kenneth Stein, chief medical officer, Rhythm Management, Boston Scientific, says, “We are eager to present new evidence supporting our modular approach to leadless pacing and defibrillation.”
